Professor of Functional Neuroanatomy & Clinical Professor of Neurology – Liège University, Belgium
Past President and Chairman of the Scientific Subcommittee of the International Headache Society
Professor Schoenen’s research interests include the pathophysiology & therapy of migraine and headaches (clinical and animal research ) and the plasticity and regeneration in the adult CNS (model of spinal cord injury & effects of cellular & molecular therapies)
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.
Lasmiditan is a member of a novel chemical class called "ditans." Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.